Atossa Therapeutics (NASDAQ:ATOS – Get Free Report) is anticipated to release its earnings data before the market opens on ...

Atos named Pierre-Yves Jolivet as executive vice president and said that he will also take the helm of Eviden and Atos's cyber business. The French IT company said late Tuesday that as part of his new ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

Aptose Biosciences shares are trading lower by 53.7% during Tuesday's session. The company announced it is going to delist from the Nasdaq.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, March 17, 2025. REUTERS/Staff/File Photo World stock markets and oil prices tumbled and investors ...

US stock futures fell on Sunday as investors braced for the broadest set yet of President Trump's tariffs to be enacted this week, including an April 2 bonanza that Trump has taken to referring to ...

Shares of Aptose Biosciences fell after the company said it was being delisted from Nasdaq. The stock dropped 41% to $1.87 on Tuesday, at one point hitting a 52-week low of $1.35. Shares have lost two ...

Mr. Cooper stock rises after mortgage giant Rocket announces a $9.4 billion deal to buy the company Mortgage giant Rocket Companies (RKT) announced Monday that it is acquiring its top competitor ...

Atossa Genetics Inc. (ATOS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- ...